Open AccessProgress toward the development of a bacterial vaccine vector that induces high‐titer long‐lived broadly neutralizing antibodies against HIV‐1
Author(s) -
Fouts T.R.,
DeVico A.L.,
Onyabe D.Y.,
Shata M.T.,
Bagley K.C.,
Lewis G.K.,
Hone D.M.
Publication year - 2003
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00067-1
Subject(s) - virology , antibody , hiv vaccine , biology , human immunodeficiency virus (hiv) , immune system , vector (molecular biology) , immunology , neutralizing antibody , titer , aids vaccines , vaccine trial , recombinant dna , gene , genetics
Conformationally constrained HIV‐1 Env and gp120 immunogens induce broadly cross‐reactive neutralizing antibodies. Thus, it is now feasible to rationally design an HIV‐1 vaccine that affords protection through humoral mechanisms. This paper reviews our progress toward the development of an oral bacterial vaccine vector that is capable of delivering an HIV‐1 DNA vaccine to host lymphoid tissues and inducing broadly neutralizing antibodies to HIV‐1 in the mucosal and systemic immune compartments.